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Trace amine-associated receptors (TAARs) belong to the class A G-protein-coupled
receptors (GPCR) and are evolutionary related to aminergic receptors. TAARs have been
identified to mediate effects of trace amines. TAAR1 signaling is mainly mediated via
activation of the Gs/adenylyl cyclase pathway. In addition to classical trace amines,
TAAR1 can also be activated by the thyroid hormone derivative 3-iodothyronamine
(3-T1AM). Pharmacological doses of 3-T1AM induced metabolic and anapyrexic effects,
which might be centrally mediated in the hypothalamus in rodents. However, the
observed anapyrexic effect of 3-T1AM persists in Taar1 knock-out mice which raises
the question whether further GPCRs are potential targets for 3-T1AM and mediate the
observed physiological effect. Anapyrexia has been observed to be related to action on
aminergic receptors such as the serotonin receptor 1b (5-HT1b). This receptor primarily
activates the Gi/o mediated pathway and PLC signaling through the Gβγ of Gi/o. Since
the expression profiles of TAAR1 and 5-HT1b overlap, we questioned whether 3-T1AM
may activate 5-HT1b. Finally, we also evaluated heteromerization between these two
GPCRs and tested signaling under co-expressed conditions. In this study, we showed,
that 3-T1AM can induce Gi/o signaling through 5-HT1b in a concentration of 10µM.
Strikingly, at 5-HT1b the ligand 3-T1AM only activates the Gi/o mediated reduction of
cAMP accumulation, but not PLC activation. Co-stimulation of 5-HT1b by both ligands
did not lead to additive or synergistic signaling effects. In addition, we confirmed the
capacity for heteromerization between TAAR1 and 5-HT1b. Under co-expression of
TAAR1 and HTR1b, 3-T1AM action is only mediated via TAAR1 and activation of 5-HT1b
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is abrogated. In conclusion, we found evidence for 5-HT1b as a new receptor target for
3-T1AM, albeit with a different signaling effect than the endogenous ligand. Altogether,
this indicates a complex interrelation of signaling effects between the investigated GPCRs
and respective ligands.
Keywords: trace amine-associated receptor 1 (TAAR1), serotonin receptor 1b (5-HT1b), 3-T1AM, signal
transduction, biased signaling, trace amines
INTRODUCTION
The trace amine associated receptor 1 (TAAR1) belongs to the
class A G-protein-coupled receptors (GPCR) and is evolutionary
related to the aminergic receptors (Krautwurst, 2008). TAAR1
activation leads to Gs signaling and is presumed to be
involved in neurocognition and neurodegeneration (Zucchi
et al., 2014; Pei et al., 2016). The receptor is activated by
biogenic trace amines such as β-phenylethyl amine (PEA),
tyramine (TYR) and octopamine (OA) (Borowsky et al., 2001;
Lindemann and Hoener, 2005). TAAR1 was also found to be
activated by amphetamines (Bunzow et al., 2001; Harkness
et al., 2015), suggesting its involvement in methamphetamine-
induced hypothermia (Miner et al., 2017). In addition to trace
amines and synthetic ligands, the thyroid hormone derivative
3-iodothyronamine (3-T1AM) is another agonistic ligand for
TAAR1 (Scanlan et al., 2004; Kleinau et al., 2011).
Interestingly, 3-T1AM is a promiscuous ligand as it binds
to other GPCRs such as TAAR5 (Dinter et al., 2015b), the β2-
adrenoreceptor (ADRB2) (Dinter et al., 2015a) and the α2A-
adrenoreceptor (ADRA2A) (Dinter et al., 2015a). One of the
peculiar functions of pharmacological doses, is its inducing of
anapyrexia (Gachkar et al., 2017), which is very different to
the classical actions of thyroid hormones (Scanlan et al., 2004;
Gachkar et al., 2017). However, in mice with targeted deletion
of Taar1, the anapyrexic 3-T1AM effect persisted (Panas et al.,
2010), indicating that this effect is not mediated via TAAR1
exclusively and that other 3-T1AM targets must be proposed to
mediate the anapyrexic affect. Aminergic receptors are potential
candidates for 3-T1AM action. It should be of note that TAAR1
arose from gene duplication of serotonin receptors (Lindemann
et al., 2005) and, as a consequence, comparing it with other
aminergic receptors showed strong similarities in the ligand
binding pocket (Kleinau et al., 2011).
We aimed to answer two questions: Firstly, whether serotonin
receptors might be targets that could explain 3-T1AM ligand
induced anapyrexic action in Taar1 knock-out mice, given the
incompletely clarified physiological role of the TAAR1 ligand
3-T1AM (Panas et al., 2010). While the full functionality of 5-
HT1b is not yet understood, its involvement in depression-like
behavior (Nautiyal and Hen, 2017), mediation of aggression and
impulse control (Bouwknecht et al., 2001) as well as induction of
anapyrexia (Bouwknecht et al., 2002) are known. Therefore, we
tested the signaling properties of this receptor in interplay with
the TAAR1 ligand 3-T1AM.
Secondly, we asked whether TAAR1 can interact with the
serotonin receptor 1b (5-HT1b) in heteromeric complexes.
TAAR1 and 5-HT1b are co-expressed in the hypothalamus
(Pazos and Palacios, 1985; Borowsky et al., 2001; Lindemann
et al., 2008), particularly in the preoptic area as the center of
body temperature regulation. Such interaction would have an
impact in the case of 3-T1AM action on both receptors and it was
our aim to also decipher the signaling spectrum under receptor
co-expressed conditions.
In summary, this study focused on the identification of a
GPCR interaction partner for TAAR1 and at the same time
provided a new aminergic human GPCR for 3-T1AM action that
should be related to the anapyrexic effects induced by this ligand.
METHODS
Cloning of Plasmid Constructs
Melanocortin-3 receptor (MC3R), 5-HT1b, ADRA2A, and
TAAR1 were amplified from genomic DNA, cannabinoid 1-
receptor (CB1R) was cloned from human brain cDNA. Human
Ghrelin-receptor (GHSR) cDNA was purchased from UMR
cDNA Resource Center, Rolla, MO, USA. For fluorescent
resonance energy transfer (FRET) measurements, cAMP and
luciferase assay TAAR1 was tagged at the N-terminus with
the first nine amino acids of the β2-adrenoreceptor (ADRB2),
resulting in βTAAR1 which according to Barak et al. (2008)
enhances protein expression; subsequently, this will be referred
to as TAAR1. Barak et al. showed in their studies that
modification only lead to a higher membrane expression of
the receptor and did not alter the signaling properties, a
finding which we can confirm (Figure 1, Supplemental Figure
1). For sandwich ELISA, the genes were cloned into the
eukaryotic expression vector pcDps (provided by Torsten
Schöneberg, University of Leipzig, Germany). Constructs were
N-terminally tagged with a hemagglutinin epitope (NHA,
50-YPYDVPDYA-30) or C-terminally tagged with a Flag epitope
(C-Flag, 50-DYKDDDDK-30). The same plasmids were also
used for cAMP and luciferase activity measurements. Only
βTAAR1 was cloned without further tags into the expression
vector pcDps for cAMP and luciferase assays. For FRET, the
cDNAs were cloned into pECFP-N1 and pEYFP-N1 (Clontech
Laboratories, USA). Plasmids were sequenced and verified by
BigDye-terminator sequencing (PerkinElmer, Inc., Waltham,
MA, USA), using an automatic sequencer (ABI 3710xl; Applied
Biosystems).
Cell Culture and Transfection
Cells were grown at 37◦C in humidified air containing 5% CO2.
For sandwich ELISA, COS7 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Biochrom GmbH, Berlin,
Germany), supplemented with 10% fetal calf serum (FCS). 1
× 106 cells were seeded in 6 cm dishes and transfected with
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FIGURE 1 | 3-T1AM, but not 5-HT induces Gs signaling via TAAR1 in a concentration of 10µM. To measure Gs and Gi/o, the cAMP content was determined via
AlphaScreen technology. HEK293 were used to overexpress TAAR1. An empty vector was used for mock transfection, which showed no endogenous effect of 5-HT
or 3-T1AM (see Supplemental Figures 1A,B). (A) TAAR1 was stimulated with either 5-HT or 3-T1AM or both in a concentration of 10µM. n = 7 measured in
triplicates. (B) TAAR1 was stimulated with forskolin and either 5-HT or 3-T1AM or both in a concentration of 10µM. Results of four independent experiments
performed in triplicates are shown. For statistics, a one-way ANOVA was performed and the mean of each column compared with the mean of all other columns.
Statistical significance was defined as **p ≤ 0.01, ****p ≤ 0.0001.
Metafectene according to the manufactures protocol (Biontex,
Munich, Germany).
HEK293 were cultured in MEM (Biochrom GmbH, Berlin,
Germany) with 5% FCS and non-essential amino acids
(Biochrom AG, Berlin, Germany). For FRET experiments
HEK293, cells (1× 105 cells/ Ø 35mm dish) were seeded in poly-
L-lysine coated FluoroDishes (World Precision Instruments,
Sarasota, FL, USA). Twenty-four hours later, the cells were
transfected with 1 µg DNA per well and 4.5 µl GeneJuice (EMP
Millipore Corp., Billerica, MA, USA). For cAMP and nuclear
factor of activated T-cells luciferase (NFAT-luc) measurements,
HEK293 cells were seeded in poly-L-lysine coated (Biochrom
GmbH, Berlin, Germany) 96-well plates (1.5 × 104 cells/well).
Transient transfection of HEK293 cells was performed 24 h after
seeding in supplement-free Advanced MEM (Life Technologies,
Carlsbad, CA, USA), using Metafectene with 0.45 µg DNA per
well and 0.45 µL Metafectene per well.
Determination of Receptor Oligomerization
by Sandwich Elisa and Fluorescence
Resonance Energy Transfer (FRET)
The sandwich ELISA was performed as previously described
by Piechowski et al. (2013) to investigate protein-protein
interaction. COS7 cells were used since they are more robust
than HEK293 and withstand the washing protocol better. An
NHA tagged TAAR1 was co-transfected with a C-Flag tagged
5-HT1b or an NHA tagged 5-HT1b was co-transfected with a C-
Flag tagged TAAR1, further referred to as reversely tagged. As
tags had no influence on the results, data was pooled. As positive
control, the growth hormone secretagogue receptor (GHSR)
homodimer was used (Kern et al., 2012), while the rat muscarinic
3 receptor (rM3R) served as the non-interacting protein (NIP).
Single transfection of the NHA tagged receptor was used as
negative control. Cells were lysed 48 h after transfection and
transferred to an anti-Flag-M2 (Sigma-Alderich, St. Louis, MO,
USA) coated plate. Thereafter, a biotin-labeled anti-HA-MAB
(Roche) was added for 2 h. Color reaction was carried out by
using a streptavidin-labeled HRP (BioLegend, San Diego, CA,
USA) to convert o-phenylendiamine. Absorption was measured
at 450 nm with correction at 620 nm using an Anthos Reader
2001 (AnthosLabtech Instruments, Salzburg, Austria). Protein
concentrations were analyzed with the Biuret method using a
BCA Protein Assay Kit (ThermoFisher Scientific, Inc., Waltham,
MA, USA) in accordance with the manufacturer’s protocol.
FRET was used to confirm the dimerization result of the
Sandwich ELISA. Acceptor bleaching was done as previously
described (Tarnow et al., 2008). A CFP tagged receptor and an
YFP tagged receptor were co-transfected including vice versa
experiments. MC3R and GHSR were used as positive control
(Rediger et al., 2011), MC3R and CB1R as negative and rM3R
as NIP. Cells which expressed CFP and YFP-tagged receptors
were chosen 72 h after transfection. Subsequently, YFP was
photo-bleached at 512 nm 0.5 s for 10 cycles, followed by 20
cycles of bleaching and measuring CFP and YFP. The increased
CFP-emission was measured at excitation at 410 nm for 0.5 s.
FRET efficiency was calculated as follows: E = (FCFPmax –
FCFPmin)/FCFPmax. A stable protein-protein interaction is defined
by a FRET efficiency between 8 and 25% (Rediger et al., 2009).
Detection of Gs and Gi/o Signaling via
cAMP Accumulation
Gs and Gi/o signaling were determined by measuring cAMP
accumulation using the AlphaScreen technology (PerkinElmer
Life Science, Boston, MA, USA) as previously described
(Kleinau et al., 2011). MC3R was used as NIP. 48 h after
transfection, stimulation was performed by using a stimulation
buffer (138mM NaCl, 6mM KCl, 1mM [MgCl∗26H2O], 5.5mM
glucose, 20mM HEPES, 1mM [CaCl∗22H2O], 1mM IBMX). For
Gs signaling, cells were incubated for 45min with either 3-
T1AM (Santa Cruz Biotechnology, Dallas, TX, USA), serotonin
(5-HT, Sigma-Alderich, St. Louis, MO, USA) or both in a
concentration of 10µM. For Gi/o pathway examination, cells
Frontiers in Pharmacology | www.frontiersin.org 3 March 2018 | Volume 9 | Article 222
Bräunig et al. 3-T1AM in Interplay With TAAR1 and 5-HT1b
were co-stimulated with 50µM forskolin (FSK, AppliChem
GmbH, Darmstadt, Germany) to activate the adenylyl cyclase.
Substance incubation was done at 37◦C with 5% CO2 and
stopped after 20min by discarding the medium. Cells were lysed
at 4◦C on a shaking platform. Intracellular cAMP accumulation
was determined by a competitive immunoassay based on the
AlphaScreen assay kit and measured using a Berthold Microplate
Reader (Berthold Technologies GmbH & Co. KG, Bad Wildbad,
Germany). If cAMP values exceeded the possible measurement
range, samples were diluted and the dilution factor afterwards
incorporated into the cAMP concentrations.
Determination of PLC Activation by a
Luciferase Reporter Gene Assay
Phospholipase C (PLC) activationwasmeasured via the luciferase
activity of a reporter gene (NFAT-luc, Promega, Madison, USA)
as previously described (Cheng et al., 2010). HEK293 were co-
transfected with a plasmid containing the NFAT and firefly
luc reporter gene (NFAT-luc, pGL4.33), together with either
receptor or empty vector plasmid DNA (mock transfection) in
an equimolar concentration (0.45 µg plasmid per well). The
thyrotropin (TSH) receptor served as a positive control and
was stimulated with 100mU/ml bovine TSH (Sigma-Alderich,
St. Louis, MO, USA) (Winkler et al., 2010). For the PTX assay
ADRA2A as Gi coupled receptor was used as positive control.
Forty-eight hours post transfection, cells were incubated for
6 h with 3-T1AM and/or 5-HT in supplement-free MEM at 37◦C
with 5% CO2. The media was removed and cells lysed for 15min
on a shaking platform at room temperature using 50 µl of 1x
passive lysis buffer (PLB, Promega,Madison, USA). To determine
luciferase activity, 10 µL sample were transferred to a black
96-well plate. Forty microliter luciferase substrate (Promega,
Madison, USA) were automatically injected using the Berthold
Microplate Reader and immediately measured.
Docking of Ligands Into hTAAR1 and
5-HT1b Structures
Our objective was to receive general and detailed insights into
potential binding modes of 3-T1AM and 5-HT at the human
TAAR1 and the 5-HT1b respectively. For this purpose, we used
an already described TAAR1model (Kleinau et al., 2011) that was
based on the solved ADRB2 structure (Cherezov et al., 2007) and
the recently solved 5-HT1b crystal structure (PDB entry 4IAQ)
(Wang et al., 2013). Both inactive receptor conformations of the
evolutionary related receptors were used for docking 3-T1AM
and 5-HT into the conserved binding pocket of the aminergic
receptors (Kleinau et al., 2011). For structure modeling, Sybyl
X2.0 (Certara, NJ, US) and AMBER F99 force field for energy
minimization and short molecular dynamics were used.
First, the co-crystallized ligand and the fusion protein
apocytochrome BRIL (fused with the receptor ICL3) were
deleted from the 5-HT1b structure. Secondly, 5-HT was placed
between two known interaction points with the receptor; (i) a
highly conserved aspartate (Vilar et al., 2011) in transmembrane
helices (TMH) 3 (Asp129, D3.32 Ballesteros & Weinstein
numbering Ballesteros et al., 1995), and (ii) a threonine in
TMH5 (Thr213, T5.43) (Huang, 2003). Both putative contacts
were defined as spatial constraints between ligand and receptor
with a distance of 2.0 Å. This system was than energetically
minimized by conjugate gradient minimization until converging
at a termination gradient of 0.1 kcal/mol∗Å. The resulting
complex was refined by molecular dynamics simulations with
unconstraint receptor side chains and ligand atoms (300K, 1 ns,
constrained backbone atoms of the backbone). The procedure of
complex minimizations and dynamic simulations was repeated
twice. Finally, the spatial distance constraints of supposed ligand
receptor contacts were deleted and the complex refined by
molecular dynamics (1 ns) whereby only the receptor backbone
atoms were constraint, followed by energetic minimization
without any constraint. The same principle protocol and initial
contact points were used for docking the ligand 3-T1AM into the
5-HT1b structure.
For comparability purposes, the described general steps were
also used for docking the ligands 5-HT and 3-T1AM into the
hTAAR1 model, albeit with a small deviation in the initial ligand
orientation. In TMH5, the putative ligand/receptor contact was
initially defined to Thr1945.42 as the corresponding position to
Thr213 of the 5-HT1b is Phe195 in TAAR1, which rules out a
hydrophilic interaction of this position with the hydroxyl-group
of the ligands.
Statistical Analysis
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA)
was used to visualize and analyze the data. Data are indicated as
mean ± standard error of the mean (SEM). Statistical analysis
was performed by a one-way ANOVA, followed by Tukey’s
honest significant difference post hoc test. To analyze receptor
co-expression, a two-way ANOVA was performed, followed by
Sidak’s multiple comparisons test. The statistical significance was
set to ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001 and ∗∗∗∗p ≤ 0.0001.
RESULTS
TAAR1 Signaling Induced by Different
Ligands
It is known that 3-T1AM stimulates Gs/adenylyl cyclase
signaling via TAAR1 (Kleinau et al., 2011). Here, we stimulated
TAAR1-transfected cells with 10µM 3-T1AM which resulted
in cAMP accumulation that was significantly over basal
signaling (Figure 1A, Supplemental Figure 2A). No 3-T1AM-
induced signaling of cells was observed after mock transfection
(Supplemental Figure 1A). In contrast to rhesus monkey TAAR1
(Xie et al., 2008), human TAAR1 can only be activated to a lesser
degree in cAMP accumulation by serotonin (5-HT, Supplemental
Figure 2B). It should be noted that recent reports suggest
that 5-HT may activate other aminergic receptors differently
to serotonin receptors, which again confirms the principle
possibility of amine ligand promiscuity (Qi et al., 2017). To test
whether 5-HT acts as a potential antagonist on TAAR1, co-
stimulation of 3-T1AM and 5-HT in equimolar concentrations
was carried out, which resulted in signaling identical to 3-T1AM
stimulation alone, thus making an antagonistic activity of 5-HT
at TAAR1 unlikely (Figure 1A).
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TAAR1 stimulated with 10µM 5-HT or 3-T1AM revealed
no significant Gi/o signaling (Figure 1B), an effect that is
comparable to mock transfected cells (Supplemental Figure 1B).
3-T1AM Activates Gi/o Signaling at the
5-HT1b
To investigate signaling activity at 5-HT1b, the receptor-
transfected cells were treated with the endogenous agonist 5-HT
as well as with 3-T1AM at a concentration of 10µM (Figure 2A).
5-HT1b is known to predominantly signal via Gi/o activation
(Bouhelal et al., 1988). In line with this, we also did not observed
any activation of Gs being stimulated by either 5-HT or by
3-T1AM (Figure 2A). As previously reported, 5-HT does induce
a strong activation of Gi/o (determined as a 50% reduction of
forskolin-activated adenylyl cyclase). Most remarkably, 3-T1AM
also activates 5-HT1b by reducing adenylyl cyclase activity by
30% (Figure 2B). It should be noted that no synergistic effect
of both ligands was observed and the reduction of cAMP
accumulation is comparable to stimulation with 5-HT alone
(Figure 2B).
To ensure that this effect was indeed due to Gi/o activation,
5-HT1b transfected cells were incubated with pertussis toxin
(PTX), inhibiting Gi/o signaling. After pre-incubation with PTX,
signaling mediated by 5-HT1b was completely blocked for both
ligands (Supplemental Figure 3A).
Different Signaling Properties of 5-HT and
3-T1AM at the 5-HT1b
As of writing, phospholipase C (PLC) activation is not reported
for TAAR1. In line with this, we also confirmed that 3-
T1AM and 5-HT do not activate PLC via an NFAT reporter
at TAAR1 (Figure 3A). In addition, the mock transfected cells
showed no activation of PLC upon 5-HT or 3-T1AM challenge
(Supplemental Figure 1C).
However, 5-HT1b can activate PLC signaling pleiotropically as
a secondary pathway via Gβγ of Gi/o (Dickenson and Hill, 1998;
Berg and Clarke, 2001). For this reason, we tested PLC signaling
of 5-HT and 3-T1AM at 5-HT1b and could confirm that 5-HT
induced PTX-sensitive PLC activation 3.7-fold; however, no PCL
signaling was detected for 3-T1AM (Figure 3B, Supplemental
Figures 3B,C). This finding classifies 3-T1AM as a biased ligand
at the 5-HT1b. This is also supported by the co-stimulation
results where the binding of 3-T1AM to 5-HT1b reduces the PLC
activation through 5-HT to only 2.2-fold (Figure 3B).
TAAR1 and 5-HT1b Can Constitute
Heteromeric Complexes
We tested for a potential TAAR1/5-HT1b interaction or close
spatial distance between the receptors with two independent
methods. Determination of receptor heteromers with differed N-
and C-terminally tagged receptors was performed for TAAR1
and 5-HT1b. In comparison to the TAAR1/D2R heteromer,
TAAR1 interaction with 5-HT1b is at the same level and
stronger in relation to the negative control (Figure 4A). To
verify obtained data by means of a second method, we applied
FRETmeasurements.We demonstrated an interaction of TAAR1
and 5-HT1b as the FRET efficiency equals that of the already
described heteromer GHSR/MC3R (Figure 4B; Rediger et al.,
2009), while the negative control and TAAR1 combined with
an non interacting receptor have significantly lower FRET
efficiencies.
To obtain deeper insights into the functional properties of this
indicated putative interaction, we tested signaling properties of
each receptor as individually transfected into cells, co-expressed
and by stimulation with their respective ligands.
Co-expression and Co-stimulation of
TAAR1 and 5-HT1b Results in a Modified
Signaling Outcome
3-T1AM application at cells with co-expressed TAAR1 and 5-
HT1b resulted in Gs signaling levels comparable to TAAR1
expression alone (Figure 5A). Additionally, co-stimulation by 3-
T1AM and 5-HT in cells with co-expressed receptors, led to
reduced levels of Gs mediated signaling which is caused by Gi/o
activation through 5-HT and 3-T1AM at the 5-HT1b.
Interestingly, when TAAR1 and 5-HT1b are co-expressed, 3-
T1AM only exerts Gs activation, as is indicated by comparable
signaling activity of 3-T1AM for TAAR1+NIP and TAAR1+ 5-
HT1b (Figure 5B). This finding indicates that the Gi/o signaling
effect of 3-T1AM at the 5-HT1b is lost in the heteromeric
constellation. Furthermore, the effect of 5-HT at the heteromer
is not as strong as when 5-HT1b is expressed alone (FSK-
induced cAMP amount reduced by 40% for TAAR1/5-HT1b
and by 50% for 5-HT1b). PLC activation was not altered
through co-expression of TAAR1 and 5-HT1b (Supplemental
Figure 3D).
Putative Interactions and Binding Modes of
3-T1AM and 5-HT With TAAR1 and 5-HT1b
The principal ligand binding site and ligand/receptor contact
point for aminergic receptors are well known from determined
crystal structures, bioinformatic approaches and mutagenesis
studies (e.g., Cherezov et al., 2007; Tan et al., 2008; Vilar
et al., 2011; Warne et al., 2011; Wichard et al., 2011).
Therefore, we initially placed 5-HT and 3-T1AM into the empty
putative binding side, located between the extracellular loops
(EL) EC2 and transmembrane helices (TMH) 3, 5, 6, and
7 (Figure 6A) of the TAAR1 model and the 5-HT1b crystal
structure, while taking known ligand/receptor contact points
as constraints into consideration (see section Materials and
Methods). These structural complexes where refined by short-
time molecular dynamics and energetically optimized by energy
minimization. The resulting models provided information
on the putative binding modes of both ligands into these
receptors. Comparison of the receptor side chains covering
the ligand binding-pockets revealed that essential residues are
conserved between these aminergic receptors. However, small
deviations can also be observed and are relevant for the
differences observed for ligand binding contacts (Supplemental
Figure 4).
5-HT binds into TAAR1 in a comparable mode as is
supposed for 5-HT in 5-HT1b (Figures 6B,C). However, in the
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FIGURE 2 | The TAAR1 agonist 3-T1AM can activated Gi/o signaling through 5-HT1b, but not Gs signaling. To measure Gs and Gi/o, the cAMP content was
determined via an AlphaScreen technology. HEK293 were used to overexpress 5-HT1b. An empty vector was used for mock transfection, which showed no
endogenous effect of 5-HT or 3-T1AM (see Supplemental Figures 1A,B). (A) 5-HT1b was stimulated with either 5-HT, 3-T1AM or both in a concentration of 10 µM.
n = 5 measured in triplicates. (B) 5-HT1b was stimulated with forskolin and either 5-HT, 3-T1AM or both in a concentration of 10µM. n = 13 measured in triplicates.
For statistics, a one-way ANOVA was performed and the mean of each column was compared with the mean of all other columns. Statistical significance was defined
as ***p ≤ 0.001, ****p ≤ 0.0001.
FIGURE 3 | 3-T1AM is not able to activate PLC via TAAR1 or 5-HT1b. Activation of PLC was measured by NFAT reporter gene assay. HEK293 were used to
overexpress TAAR1 or 5-HT1b. An empty vector was used for mock transfection, which showed no endogenous effect of 5-HT or 3-T1AM (Supplemental Figures
1C). As positive control HEK293 were transfected with TSHR and stimulated with TSH (100 mU/mL) for 6 h (data ± SEM basal luciferase activity: 6931 ± 395.8 TSH
stimulation: 411,660 ± 64,212). TAAR1 or 5-HT1b were stimulated with either 5-HT, 3-T1AM or both in a concentration of 10µM for 6 h in DMEM without FCS.
(A) TAAR1 over expression, n = 4 measured in triplicates. (B) 5-HT1b over expression, n = 14 measured in triplicates. For statistics, a one-way ANOVA was
performed and the mean of each column was compared with the mean of all other columns. Statistical significance was defined as **p ≤ 0.01, ****p ≤ 0.0001.
5-HT1b/5-HT complex, the ligand interacts with Thr213 in
TMH5 via a hydrogen bond, which cannot be observed for 5-
HT in TAAR1. This can be explained by a deviation in the
amino sequence at this position. In TAAR1, a phenylalanine
is located at the corresponding position (Phe195) and thus a
hydrogen bonding with the ligand hydroxyl-group cannot be
established. It could be that this interaction between TAAR1 and
5-HT alternatively occurs with T194 (adjacent amino acid) which
is consecutive to Phe195. In conclusion, besides a conserved
ligand orientation of 5-HT in TAAR1 and 5-HT1b, the essential
interaction is different between both binding poses.
3-T1AM binds to the 5-HT1b in an almost comparable way to
5-HT (Figure 6C), albeit with a small structural shift that is likely
due to the larger dimension of 3-T1AM.
The most significant difference in ligand binding can be
observed between the complexes 3-T1AM/TAAR1 and 3-
T1AM/5-HT1b. In TAAR1, the ligand 3-T1AM is located
between the TMH3 (anchored at Asp103) and the aromatic
moiety is oriented between TMH3, TMH4 and TMH5, whereby
the hydroxyl-group potentially interacts with asparagine 164
at the transition between the EC2 and TMH4 (Figure 6B and
Supplemental Figure 4). This stands in strong contrast to
the 3-T1AM binding in 5-HT1b (Figure 6C). The explanation
for this can be found in the two different amino acids
Ser190 (TAAR1) and Tyr208 (5-HT1b) at the corresponding
positions in TMH5. While the aromatic hydroxyphenyl ring
of Tyr208 in 5-HT1b spatially blockades the orientation
of the aromatic phenyl ring of the ligand, this region is
accessible for the ligand in TAAR1 as the serine side chain
is short and not bulky like the corresponding tyrosine.
Therefore, these studies suggest an additional or newly formed
hydrogen bond between 3-T1AM and TAAR1 (with Asn164
in the EC2) as opposed to the putative binding mode with
5-HT1b.
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FIGURE 4 | TAAR1 and 5-HT1b can interact. Sandwich ELISA and FRET were performed to investigate dimerization. (A) For sandwich ELISA, receptor pairs were
overexpressed in COS-7 cells, receptors were NHA- and FLAG-tagged and vice versa. The homodimers GHSR and TAAR1, as the heterodimer TAAR1 and DRD2
were used as positive control; TAAR1 and rM3R were used as negative control. NHA control are cells over expressing NHA-tagged TAAR1, 5-HT1b, DRD2, and
GHSR. Data are shown as mean ± SEM of fold over mock transfection. Data were pooled from four to eight independent assays measured in three replicates. For
statistical analysis, a one-way ANOVA was performed in relation to mock transfection. (B) To determine FRET efficiency, HEK293 overexpressed receptor pairs, one
being CFP and one the YFP tagged and vice versa. The heterodimer GHSR and MC3R was used as positive control, CB1R and MC3R as negative control. rM3R was
used as NIP for TAAR1. Compared to GHSR and MC3R dimers, the negative control and TAAR1 with the NIP showed no protein-protein-interactions, whereas
TAAR1 and 5-HT1b co-expression did. Data were pooled from 11 to 19 cells and a one-way ANOVA was performed and the mean of each column was compared
with the mean of all other columns. Statistical significance was defined as *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001.
FIGURE 5 | Modification of signaling properties of 3-T1AM at the TAAR1/5-HT1b heteromer. To measure Gs and Gi/o activation, cAMP accumulation was measured
via an AlphaScreen technology. For control, HEK293 expressing TAAR1 and a non-interacting protein (MC3R) were used (gray bars) and compared with TAAR1 and
5-HT1b co-expression (black bars). 3-T1AM does not induce Gi/o activation in the heteromeric constellation and the effect of 5-HT is lessened. Data were pooled
from 6 to 10 independent assays and measured in triplicates. For statistics, a one-way ANOVA was performed to compare the ligands, a two-way ANOVA was used
to compare TAAR+NIP and TAAR+5-HT1b and considered significant with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (A) Cells were stimulated with either
5-HT, 3-T1AM or both in a concentration of 10µM. (B) For Gi/o, cells were additionally co-stimulated with forskolin and the ligands.
DISCUSSION
Our aim in this study was to elucidate whether 5-HT1b is a
potential 3-T1AM target. We wanted to verify the hypothesis
that an interplay between TAAR1 and other aminergic receptors
like the 5-HT1b should modify signaling properties as is already
known from other heteromeric GPCRs (Rozenfeld and Devi,
2011). For several assays, we used an N-terminally tagged
TAAR1. Besides GPCR trafficking, the N-terminus is relevant
for ligand binding, signal transduction and even receptor
interaction, with point mutations and deletions predominantly
leading to reduced receptor functionality (Uddin et al., 2012;
Belmer et al., 2014; Coleman et al., 2017). However, nearly all
class A GPCRs possess a short N-terminus and we did not
observe that an extension of the ADRB2 with nine amino acids
lead to a different signaling of TAAR1 (Figure 1A, Supplemental
Figure 2A). Additionally, both interaction assays purpose a
protein-protein-interaction between TAAR1 and HTR1b, even
though an unmodified TAAR1 was used for the sandwich ELISA
and a tagged one for FRET.
Biased Signaling of 3-T1AM at the 5-HT1b
It is significant that 3-T1AM can modulate 5-HT1b signaling
as reported here (Figure 2), since this induced signal is biased
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FIGURE 6 | General and detailed insights into potential binding modes of 3-T1AM and 5-HT at the hTAAR1 and the 5-HT1b. (A) This backbone illustration visualizes
the general architecture of TAAR1. The principle ligand binding site and preferred ligand/receptor contact points are known (e.g., Cherezov et al., 2007; Tan et al.,
2008; Vilar et al., 2011; Warne et al., 2011; Wichard et al., 2011). (B,C) Comparison of receptor side chains in both receptors covering the ligand binding-pockets
revealed that essential residues are conserved, however, small deviations in the amino acid constitution of the binding pockets might be of significance (indicated by
different coloring). 5-HT binds into TAAR1 in a comparable mode as supposed for 5-HT in the 5-HT1b. (B,C). In the 5-HT1b/5-HT complex the ligand interacts with
Thr213 in TMH5 via hydrogen bonding, which cannot be observed for 5-HT in TAAR1. It should be noted that 3-T1AM binds to the 5-HT1b in a nearly comparable way
as was found for 5-HT (C) In TAAR1, the ligand 3-T1AM is located between the Asp103 in TMH3 and the aromatic moiety is located between TMH3-4-5, whereby
according to these supposed complexes the hydroxyl-group interacts with Asn164 at the transition between the EC2 and TMH4 (B). This is vastly different to 3-T1AM
binding in the 5-HT1b (C), which is reasoned by amino acids Ser190 (TAAR1) and Tyr208 (5-HT1b) at corresponding positions in TMH5. While the bulky aromatic ring
of Tyr208 in 5-HT1b blockades the orientation of ligands between TMH3-4-5, in TAAR1 this region is accessible for the ligand because of the smaller serine side chain.
when compared to 5-HT action on this receptor in terms of
PLC activation by Gβγ. It is known that the heterotrimeric
Gi/o protein can remain as a complex of Gα and Gβγ after
activation (Bunemann et al., 2003; Frank et al., 2005). This
finding leads to the question what physiological effects might
be influenced by 3-T1AM action on this aminergic receptor,
particularly in terms of a particular signaling pathway. The 5-
HT related hormone system is evolutionary ancient and has
important functions in lower animals, even as it is involved in
behavioral tasks such as egg laying (Nichols and Sanders-Bush,
2001). In higher animals, 5-HT is involved in a variety of complex
behaviors and processes such as aggression, sleep, appetite and
mood (Nichols and Sanders-Bush, 2001). 5-HT-induced effects
are usually mediated by a group of receptors with 14 members
(Hoyer et al., 1994). Specific targeting of 5-HT-receptors for
treatment of a diverse set of pathophysiological conditions
such as depression, schizophrenia, migraine among others is
an important issue for which the functional selectivity at these
receptors comes into play (Bohn and Schmid, 2010).
For the first time, our study showed that 3-T1AM can
activate 5-HT1b in terms of Gi/o coupling, but also that
the induced signaling profile of 3-T1AM is different for
5-HT as it lacks induction of PLC signaling via Gβγ of
Gi/o. As of writing, 3-T1AM is known to be involved in
various physiological functions (Zucchi et al., 2014) such as
thermoregulation, regulation of glucose homeostasis (Manni
et al., 2012), modulation of pain and memory (Manni et al.,
2013) as well as effects on sleep and motor activity (James et al.,
2013). After conversion of 3-T1AM to 3-iodothyroacetic acid,
modulation of the histaminergic system (Laurino et al., 2015) and
vasodilatation (Gachkar et al., 2017) was observed. It should be
hypothesized that some of these effects could potentially be due
to the activation of 5-HT1b rather than being related to the 3-
T1AM target TAAR1. However, differential signaling of 3-T1AM
at 5-HT1b provides an opportunity to selectively activate the
5-HT1b in terms of a specific pathway. Further studies should
reveal whether 3-T1AM is also capable of modifying the function
of other serotonin receptors and if the action of 3-T1AM at
5-HT-receptors is involved in thermoregulation.
We further asked how these two ligands interact with their
respective receptors and how far their binding modes differ
or overlap. For this purpose, we used available structural
information and performed molecular dynamic simulations
(Figure 6 and Supplemental Figure 4). The supposed ligand
bound receptor complexes suggest three main results: (1) 5-HT
can bind with a near identical orientation into both receptors,
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whereby small differences between the receptors in the amino
acids of TMH5 are likely associated with slight deviations
in the putative intermolecular hydrogen bonds. (2) 5-HT is
located partially different in TAAR1 compared to 3-T1AM,
which can be explained by differences in the ligand dimensions
and intermolecular contacts to TMH5 which could also explain
why this ligand induces lower Gs mediated signaling at this
receptor. (3) Moreover, while 3-T1AM can be characterized by
a comparable binding mode in the 5-HT1b as supposed for
5-HT, which is in line with the Gi/o activation by 3-T1AM
at this receptor identified in our study, binding of this ligand
into the TAAR1 is significantly different. This is likely due to
the specific amino acid composition surrounding the ligand
binding site (Figures 6B,C). In contrast to the orientation of 3-
T1AM in 5-HT1b, 3-T1AM in TAAR1 is orientated more toward
TMH4 and the EC2, which can be explained by different amino
acids in TMH5 covering the ligand binding pockets (Figure 6B).
In conclusion, these molecular insights on one hand support
similarities in the investigated receptor/ligand complexes, but
on the other hand also highlight potential differences between
agonistic ligands in aminergic receptors and their associated
diverse effects on signaling.
Co-expression of TAAR1 and 5-HT1b in
Interplay With 3-T1AM and 5-HT Modulates
the Resulting Signaling Profile
By using two independent methods, sandwich ELISA and FRET,
we confirmed that TAAR1 has the potential to interact with
the 5-HT1b (Figure 1). This finding extends the physiologically
possible interactome of TAAR1 and the 5-HT1b as they are both
expressed in in the hypothalamus (Pazos and Palacios, 1985;
Borowsky et al., 2001; Lindemann et al., 2008), in the striatum
(Espinoza et al., 2011; Navailles and De Deurwaerdère, 2011)
and in the dorsal raphe nuclei (Lindemann et al., 2008; Beliveau
et al., 2017). As a result, it is of further interest how such
potential interaction or interplay may impact the functionality
of these receptors. Two general possibilities must be considered,
either heteromeric interaction itself has an impact on signaling
properties or the ligand mediated action is influenced by such
heteromerization (George et al., 2002). Moreover, the scenario
becomes even more complex if both receptors respond to the
same ligands, but with diverse signaling pathways.
Therefore, we studied the potential heteromeric complex by
experiments under co-expressed conditions and simultaneously
tested the signaling effects by individual or by co-stimulated
ligand application. Our findings on the TAAR1/5-HT1b
heteromer constitution are in accordance with several other
reports, pointing to the capacity of TAAR1 to interplay with
diverse proteins such as the D2R (Espinoza et al., 2011; Navailles
and De Deurwaerdère, 2011) or the ADRA2A (Dinter et al.,
2015b).
In our study, we observed that the 5-HT and 3-T1AM
mediated activation of Gi/o via the 5-HT1b is modified under
co-expressed receptor conditions (Figure 5B). Notably, the
action of 3-T1AM at the heteromer did not show any Gi/o
activation at 5-HT1b and the effect of 5-HT is reduced. In
principle, uncoupling of a TAAR1 interaction partner from its
signaling pathway was observed for norepinephrine-induced
ADRA2A signaling in a TAAR1/ADRA2A heteromer (Dinter
et al., 2015b). The effect we observed here is different and
we speculate that under the above described conditions, the
Gs activation induced by 3-T1AM binding at the TAAR1 is
oppositional to the Gi/o mediated effect of 5-HT1b/5-HT and 5-
HT1b/3-T1AM complexes (Figure 3). This would also suggest
that under co-expressed conditions (like for TAAR1 and the
5-HT1b in several tissues), the availability and number of
ligands (concentrations) are regulating elements for the resulting
signaling output. It was reported that for serotonin receptor
ligands, the thermic effect is concentration dependent, e.g.,
high concentrations of 5-methoxy-N,N-dimethyltryptamine (5-
MeODMT) induce hyperthermia, while lower doses result in
anapyrexia, mediated by 5HT1b and HTR2 (Gudelsky et al.,
1986).
In summary, we found in this study that 3-T1AM is a
biased ligand of 5-HT1b. Further studies will have to show if
this receptor is responsible for the 3-T1AM induced anapyrexic
effect seen in rodents or if other thermoregulatory GPCRs are
involved. Our work also underlines the complex role of TAAR1
concerning modulating signal transduction of various aminergic
GPCRs and different promiscuous ligands. Targeting of receptors
in this signaling network for therapeutically purposes might
result in a plethora of effects depending on ligand concentration
and expression profile of interacting partners in different
tissues.
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